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Abstract
Background: Thrombolytic drugs are widely used for the management of cerebral venous sinus
thrombosis patients. Several in vitro models have been developed to study clot lytic activity of
thrombolytic drugs, but all of these have certain limitations. There is need of an appropriate model
to check the clot lytic efficacy of thrombolytic drugs. In the present study, an attempt has been
made to design and develop a new model system to study clot lysis in a simplified and easy way
using a thrombolytic drug, streptokinase.
Methods: Whole blood from healthy individuals (n = 20) was allowed to form clots in a pre-
weighed sterile microcentrifuge tubes; serum was removed and clot was weighed. After lysis by
streptokinase fluid was removed and remnants of clot were again weighed along with the tube.
Percentage of Clot lysis was calculated on the basis of the weight difference of microcentrifuge
tubes obtained before and after clot lysis.
Results: There was a significant percentage of clot lysis observed when streptokinase was used.
On the other hand with water (negative control), minimal (2.5%) clot lysis was observed. There
was a significant difference between clot lysis done by streptokinase and water.
Conclusion: Our study could be a rapid and effective methodology to study clot-lytic effect of
newly developed drugs as well as known drugs.
Background
Cerebral venous sinus thrombosis (CVST) is a common
disorder that is often accompanied by significant morbid-
ity and mortality [1,2]. In anticoagulation therapy the
intravenous heparin [2,3] is the first line of treatment for
CVST, because of its efficacy, safety and feasibility. How-
ever, thrombolytic therapy, with its ability to produce
rapid clot lysis, has long been considered an attractive
alternative [4]. Thrombolytic drugs like tissue plasmino-
gen activator (t-PA), urokinase, streptokinase etc. play a
crucial role in the management of patients with CVST. In
India though streptokinase and urokinase are widely used
due to its lower cost, as compared to other thrombolytic
drugs, these are dangerous [5-9] because they might cause
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serious bleeding complications along with reocclusion
and reinfarction.
Various methods were developed to measure the clot lysis
activity of thrombolytic drugs. The best way to study
thrombolytic drugs is through in vitro clot lysis model
[10-19]. Earlier Basta et al [10] worked on artificial clots
and used ultrasound methods to measure the thrombo-
lytic activity of streptokinase. Several other models have
been reported which either uses complicated mathemati-
cal [11] or computing [12] skills, but all these methods are
very costly and not affordable in developing countries.
The above-mentioned problems demand a need of simple
and cost effective clot lytic model for measurement of clot
lysis activity of thrombolytic drugs. In the present study an
attempt has been made to develop an in-vitro clot lytic
model using a known thrombolytic drug, streptokinase.
Materials and methods
Specimen
Venous blood was drawn from healthy human volunteers
(n = 20) without a history of oral contraceptive or antico-
agulant therapy (using a protocol approved by our Insti-
tutional Ethics Committee). 500 μl of blood was
transferred to each of the previously weighed microcentri-
fuge tubes to form clots.
Streptokinase
To the commercially available lyophilized streptokinase
vial (15, 00,000 I.U.) 5 ml phosphate buffered saline
(PBS) was added and mixed properly. This suspension
was used as a stock from which appropriate dilutions were
made to observe the thrombolytic activity using the in
vitro model developed in our laboratory.
Study design
Venous blood drawn from healthy volunteers (n = 20)
was transferred in different pre weighed sterile microcen-
trifuge tube (500 μl/tube) and incubated at 37°C for 45
minutes. After clot formation, serum was completely
removed (aspirated out without disturbing the clot
formed) and each tube having clot was again weighed to
determine the clot weight (clot weight = weight of clot
containing tube – weight of tube alone). Each microcen-
trifuge tube containing clot was properly labeled and 100
μl of streptokinase along with various dilutions in sterile
distilled water (undiluted, 3:4, 1:2 and 1:3) was added to
the tubes. Water was also added to one of the tubes con-
taining clot and this serves as a negative thrombolytic con-
trol. All the tubes were then incubated at 37°C for 90
minutes and observed for clot lysis. After incubation, fluid
obtained was removed and tubes were again weighed to
observe the difference in weight after clot disruption. Dif-
ference obtained in weight taken before and after clot lysis
was expressed as percentage of clot lysis. The test was
repeated ten times with all the four dilutions of the
thrombolytic drugs (Streptokinase) in blood samples of
twenty different healthy volunteers.
Statistical analysis
The mean clot lysis percent of streptokinase with different
concentrations was compared with water using the
repeated measures ANOVA with Tukey post test. Data are
expressed as mean ± standard deviation. A p value ≤ 0.05
was considered to be statistically significant.
Results
A clear, visual representation of clot lysis is shown in fig-
ure no. 1. When 100 μl water was added to the control clot
negligible clot lysis was observed. Whereas, tubes to
which different dilutions of streptokinase was added, sig-
nificant clot lysis could be visually seen. Percent clot lysis
obtained after treating clots with streptokinase and con-
trol group is shown in figure 2. Maximum clot lysis was
observed when undiluted streptokinase (100 μl) was
added to the clots. With water 2.55% weight difference
was seen. Though undiluted streptokinase (30,000 I.U.)
showed maximum clot lysis (p = 0.004) but another three
dilutions (22,500 I.U., 15,000 I.U., 7,500 I.U.) of strep-
tokinase also showed approximately same percent of clot
lysis (p < 0.05). The mean clot lysis % of streptokinase
with all different concentration was found to differ signif-
icantly when compared with water (i.e, p < 0.05 for all the
concentrations of streptokinase).
Clot-lysis of blood samples of normal subjects (positive and  negative control) Figure 1
Clot-lysis of blood samples of normal subjects (posi-
tive and negative control). Tube no. 1 is a control clot 
(negative control) to which water was added. No clot lysis 
was observed in tube no.1; a black arrow indicates the intact 
clot. Tube no. 2–5 (positive control) was lysed by four differ-
ent concentrations of streptokinase with decreasing order. 
After dissolution of the clots, tubes were inverted and fluid 
(blue arrow) along with the remnants of clots (red arrow) 
could be clearly seen
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Discussion
This study shows in vitro dissolution of clots by four dif-
ferent dilutions of streptokinase, assayed by an in vitro
clot lysis model designed and developed in our labora-
tory. Most of the in vitro methods that were convention-
ally or currently applied to study thrombolysis have
certain limitations. Some involve complex computation
and mathematical skills that too give only theoretical pre-
diction of the outcome and most are expensive to be per-
formed in a laboratory. In context with the current
scenario we thought of developing a clot lysis model that
would be easy to perform & that should be cost effective
too.
Keeping this idea in the prime focus, weight of the clot
before lysis and after lysis was considered as appropriate
determinant of calculating clot lysis percentage. Blood
collected by the standard protocol of venipuncture was
allowed to form clots naturally and the weight difference
obtained before and after lysis was noted and clot lysis
percentage was calculated. In other methods, there are dif-
ferent parameters to analyze the extent of clot lysis. For
example, radiolabelling of factors that are actively
involved in clot lysis mechanism [13], MRI [15], ultra-
sound frequency [10], turbidity determination using
microtiter plate reader (euglobulin lysis test) [16,17],
study of fibrinolytic activity by circulating fibrinolytic
enzymes and monitoring the effect by calculating shear
rate [18,19]. All these methods are sophisticated whereas,
our model is simple and easy to perform and one can even
visually observe the lysis of clots (as shown in figure 1).
Conclusion
To check the efficacy of thrombolytic drugs or herbs one
can compare the data with positive and negative control.
In our study we took a known thrombolytic drug; strep-
tokinase as a positive control and water as a negative con-
trol. Test drug can also be analyzed in the same way. Thus,
our study could be an instant and effective methodology
to study clot lytic effect of newly developed drugs as well
as known drugs.
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